CAJ | 학술논문

目的：观察莫沙必利联合胰激肽原酶治疗糖尿病神经源性膀胱（DNB）的临床疗效及安全性。方法将2007年2月至2013年2月100例确诊患者按照平行分组的方法随机均分为对照组与观察组，各50例。两组患者均接受降糖、降压、调脂等基础治疗，观察组在此基础上应用莫沙必利联合胰激肽原酶进行治疗，比较两组疗效、治疗前后患者的膀胱残余尿量、生存质量、不良反应及随访情况等。结果对照组临床治疗总有效率为68.00％，明显低于观察组的94.00％（ P ＜0.01）；两组治疗后膀胱残余尿量均较治疗前出现明显降低（ P ＜0.05或 P ＜0.01），且观察组治疗后膀胱残余尿量与对照组治疗后相比，差异具有统计学意义（ P ＜0.05）；两组治疗后生存质量总评分较治疗前均明显升高（ P ＜0.05或 P ＜0.01），且观察组治疗后生存质量与对照组治疗后相比，差异具有统计学意义（ P ＜0.05）；两组治疗期间，均无不良反应发生；两组均获随访12个月，观察组复发率明显小于对照组（ P ＜0.01）。结论莫沙必利联合胰激肽原酶治疗糖尿病神经源性膀胱，效果显著，值得临床推广。
목적：관찰막사필리연합이격태원매치료당뇨병신경원성방광（DNB）적림상료효급안전성。방법장2007년2월지2013년2월100례학진환자안조평행분조적방법수궤균분위대조조여관찰조，각50례。량조환자균접수강당、강압、조지등기출치료，관찰조재차기출상응용막사필리연합이격태원매진행치료，비교량조료효、치료전후환자적방광잔여뇨량、생존질량、불량반응급수방정황등。결과대조조림상치료총유효솔위68.00％，명현저우관찰조적94.00％（ P ＜0.01）；량조치료후방광잔여뇨량균교치료전출현명현강저（ P ＜0.05혹 P ＜0.01），차관찰조치료후방광잔여뇨량여대조조치료후상비，차이구유통계학의의（ P ＜0.05）；량조치료후생존질량총평분교치료전균명현승고（ P ＜0.05혹 P ＜0.01），차관찰조치료후생존질량여대조조치료후상비，차이구유통계학의의（ P ＜0.05）；량조치료기간，균무불량반응발생；량조균획수방12개월，관찰조복발솔명현소우대조조（ P ＜0.01）。결론막사필리연합이격태원매치료당뇨병신경원성방광，효과현저，치득림상추엄。
Objective To investigate the clinical efficacy and safety of mosapride combined with pancreatic kallikrein in treating dia-betic neurogenic bladder(DNB). Methods 100 cases of diagnosed DNB in our hospital from February 2007 to February 2013 were randomly divided into the control group and the observation group according to the parallel grouping method,50 cases in each group. All patients received the basic treatment of reducing blood glucose,reducing blood pressure and regulating blood lipids. On this basis the observation group was given the treatment of mosapride combined with pancreatic kallikrein. The clinical efficacy,bladder residual urine amount before and after treatment,quality of life,adverse reactions and following - up,etc. were compared between the to groups. Results The total effective rate in the control group was 68. 00% ,which was significantly lower than 94. 00% in the obser-vation group( P < 0. 01);the bladder residual urine volume after treatment in the two groups was significantly reduced( P < 0. 05, P < 0. 01),moreover there was a statistical difference in the bladder residual urine volume between the two groups( P < 0. 05);ac-cording to the evaluation criteria of quality of life(QOL),the QOL scores after treatment in the two groups were significantly increased compared with before treatment( P < 0. 05,P < 0. 01),moreover there was a statistical difference in the QOL scores after treatment between the two groups ( P < 0. 05);no adverse reactions during the therapeutical process occurred in the two groups;the two groups were followed up for 12 months,the recurrence rate of the observation group was significantly lower than that of the control group( P < 0. 01). Conclusion Mosapride combined with pancreatic kallikrein has a significant effect in the treatment of DNB and is worthy to be promoted in clinic.